Taylor S, Belt R J, Joseph U, Haas C D, Hoogstraten B
Invest New Drugs. 1984;2(3):311-4. doi: 10.1007/BF00175382.
A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.
针对每三周一次大剂量给药方案的AT - 125进行了I期试验。剂量限制毒性主要表现为中枢神经系统（CNS）症状，形式为共济失调、意识模糊、幻觉和构音障碍。虽然在150 mg/m²剂量时最为严重，但在所有剂量水平均有较轻症状的报告。高剂量时恶心和呕吐为中度至重度。未发生骨髓抑制。在开发出降低药物相关中枢神经系统毒性的方法之前，不建议将此给药方案用于II期研究。
